Zymeworks Deal Expands Jazz’s Potential Oncology Presence

 
• By Alaric DeArment
  
Zymeworks and Jazz signed a deal worth up to $1.76bn for the HER2-targeting bispecific antibody zanidatamab • Source: Shutterstock

More from Immuno-oncology

More from Anticancer